Categories
Archives
- 2026
- 2025
- 2024
- 2023
Sep
09
UCB receives U.S. FDA Breakthrough Therapy Designation for CIMZIA® (certolizumab pegol) in pregnant women with antiphospholipid syndrome (APS)
Aug
31
UCB Comes to Agreement with U.S. Government to Lower the Cost of Medicine and Strengthen U.S. Manufacturing
Aug
16
Axios Names UCB a Winner of the Metro Atlanta Top Workplaces 2026 Award
Aug
05
Epilepsia Open publishes results of post hoc data analysis of FINTEPLA® (fenfluramine) in patients with Lennox-Gastaut syndrome
Jul
07
UCB Awards Annual Myasthenia Gravis Scholarships to 15 Individuals Impacted by MG in the U.S.
Jun
01
UCB Launches Career-Advancing Scholarship Program for Adults Living with Hidradenitis Suppurativa and Immediate Family Members
May
19
BIMZELX® (bimekizumab-bkzx) demonstrates superior efficacy over SKYRIZI® (risankizumab-rzaa) in psoriatic arthritis: BE BOLD Week 16 data
May
04
UCB to acquire Candid Therapeutics, building upon its existing immunology pipeline with novel T-cell engagers
Apr
17
UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science